• 1
    Denborough M. Malignant hyperthermia. Lancet 1998;352:11311136.
  • 2
    McCarthy TV, Healy JM, Heffron JJ, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990;343:562564.
  • 3
    Fujii J, Otsu K, Zorzato F, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991;253:448451.
  • 4
    Roberts MC, Mickelson JR, Patterson EE, et al. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). Anesthesiology 2001;95:716725.
  • 5
    Aleman M, Riehl J, Aldridge BM, et al. Association of a mutation in the ryanodine receptor 1 gene with equine malignant hyperthermia. Muscle Nerve 2004;30:356365.
  • 6
    Wappler F, Fiege M, Steinfath M, et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001;94:95100.
  • 7
    Aleman M, Nieto JE, Magdesian KG. Malignant hyperthermia associated with ryanodine receptor 1 (C7360G) mutation in Quarter Horses. J Vet Intern Med, 23. Doi: DOI: 10.1111/J.1939-1676.2009.0274.x.
  • 8
    The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984;56:12671269.
  • 9
    Hildebrand SV, Arpin D, Cardinet III G Contracture test and histologic and histochemical analyses of muscle biopsy specimens from horses with exertional rhabdomyolysis. J Am Vet Med Assoc 1990;196:10771083.
  • 10
    Hoffmann M, Hurlebaus J, Weilke C. Novel methods for high-performance melting curve analysis using the LightCycler 480 system. Biochemica 2007;1:1719.